应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02196 复星医药
未开盘 07-22 16:08:56
13.780
+0.200
+1.47%
最高
13.920
最低
13.460
成交量
272.85万
今开
13.540
昨收
13.580
日振幅
3.39%
总市值
367.99亿
流通市值
76.06亿
总股本
26.70亿
成交额
3,760万
换手率
0.49%
流通股本
5.52亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
复星医药(02196):新药研发投入达3002万元,市场潜力巨大
和讯网 · 07-22 19:03
复星医药(02196):新药研发投入达3002万元,市场潜力巨大
复星医药:控股子公司两款药品获注册申请受理
新京报 · 07-22 18:51
复星医药:控股子公司两款药品获注册申请受理
复星医药子公司2款新药获药品注册申请受理
北京商报 · 07-22 17:17
复星医药子公司2款新药获药品注册申请受理
复星医药(600196.SH):硝普钠注射液及氟比洛芬酯注射液药品注册申请获受理
智通财经 · 07-22 16:55
复星医药(600196.SH):硝普钠注射液及氟比洛芬酯注射液药品注册申请获受理
复星医药(600196.SH,02196)深化CNS领域布局,合作产品全球首款128通道无液氦脑磁图仪获批上市
智通财经 · 07-22 09:03
复星医药(600196.SH,02196)深化CNS领域布局,合作产品全球首款128通道无液氦脑磁图仪获批上市
复星医药登榜“中国卓越管理公司”连续获奖企业
复星医药 · 07-22 08:47
复星医药登榜“中国卓越管理公司”连续获奖企业
复星医药控股子公司复星医药产业与Kite Pharma拟对复星凯特进行同比例增资
新浪港股 · 07-22 08:31
复星医药控股子公司复星医药产业与Kite Pharma拟对复星凯特进行同比例增资
复星医药为控股子公司提供担保
新浪港股 · 07-22 08:30
复星医药为控股子公司提供担保
复星医药控股股东质押8000万股及解除质押8000万股公司股份
新浪港股 · 07-22 08:22
复星医药控股股东质押8000万股及解除质押8000万股公司股份
复星医药控股子公司重庆凯林制药自主研发的硫代硫酸钠注射液获药品注册申请受理
新浪港股 · 07-22 08:20
复星医药控股子公司重庆凯林制药自主研发的硫代硫酸钠注射液获药品注册申请受理
招募复星系旧将,水井坊再迎新帅
国际金融报 · 07-20 18:36
招募复星系旧将,水井坊再迎新帅
复星医药(600196)股东上海复星高科技(集团)有限公司质押8000万股,占总股本2.99%
证券之星 · 07-20
复星医药(600196)股东上海复星高科技(集团)有限公司质押8000万股,占总股本2.99%
复星医药(02196)控股股东质押8000万股及解除质押8000万股公司股份
智通财经 · 07-19
复星医药(02196)控股股东质押8000万股及解除质押8000万股公司股份
复星医药(02196)控股子公司重庆凯林制药自主研发的硫代硫酸钠注射液获药品注册申请受理
智通财经 · 07-19
复星医药(02196)控股子公司重庆凯林制药自主研发的硫代硫酸钠注射液获药品注册申请受理
复星医药(02196)为控股子公司提供担保
智通财经 · 07-19
复星医药(02196)为控股子公司提供担保
复星医药最新公告:控股子公司药品注册申请获受理
证券之星 · 07-19
复星医药最新公告:控股子公司药品注册申请获受理
复星医药(600196.SH)拟对合营企业复星凯特增资
智通财经 · 07-19
复星医药(600196.SH)拟对合营企业复星凯特增资
复星医药(600196.SH):硫代硫酸钠注射液药品注册申请获受理
智通财经 · 07-19
复星医药(600196.SH):硫代硫酸钠注射液药品注册申请获受理
复星医药以国际标准推进质量管理 制药产线获WHO等权威组织国际认可
证券之星 · 07-18
复星医药以国际标准推进质量管理 制药产线获WHO等权威组织国际认可
单抗概念盘中跳水,复星医药跌0.09%
自选股智能写手 · 07-18
单抗概念盘中跳水,复星医药跌0.09%
公司概况
公司名称:
复星医药
所属市场:
SEHK
上市日期:
--
主营业务:
上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。
发行价格:
--
{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":13.78,"timestamp":1721635736030,"preClose":13.58,"halted":0,"volume":2728500,"delay":0,"floatShares":551940500,"shares":2670458911,"eps":0.9563063,"marketStatus":"未开盘","marketStatusCode":0,"change":0.2,"latestTime":"07-22 16:08:56","open":13.54,"high":13.92,"low":13.46,"amount":37600030,"amplitude":0.033873,"askPrice":13.8,"askSize":3000,"bidPrice":13.78,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":0.802262174458087,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":13.58,"dividendRate":0.020964,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.8746177374007741,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":23.58,"timestamp":1721631600000,"preClose":23.38,"halted":0,"volume":10622611,"delay":0,"premium":"-45.38"}},"requestUrl":"/m/hq/s/02196/wiki","defaultTab":"wiki","newsList":[{"id":"2453357795","title":"复星医药(02196):新药研发投入达3002万元,市场潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2453357795","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453357795?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:03","pubTimestamp":1721646225,"startTime":"0","endTime":"0","summary":"这两种药品均为复星医药集团自主研发的化学药品。截至2024年6月,集团对新药1和新药2的累计研发投入分别约为人民币191万元和2811万元。目前,中国境内已有多种硝普钠制剂和氟比洛芬酯注射液获批上市。根据IQVIA CHPA数据,2023年,硝普钠制剂和氟比洛芬酯注射液在中国的销售额分别约为人民币2.23亿元和9.04亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722215653954fe29e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722215653954fe29e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"2453676370","title":"复星医药:控股子公司两款药品获注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2453676370","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453676370?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:51","pubTimestamp":1721645475,"startTime":"0","endTime":"0","summary":"复星医药(600196)7月22日晚间公告,控股子公司重庆药友制药有限责任公司于近日收到国家药品监督管理局关于硝普钠注射液、氟比洛芬酯注射液的药品注册申请获受理的通知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407223136957159.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407223136957159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2453751675","title":"复星医药子公司2款新药获药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2453751675","media":"北京商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453751675?lang=zh_cn&edition=full","pubTime":"2024-07-22 17:17","pubTimestamp":1721639850,"startTime":"0","endTime":"0","summary":"北京商报讯(记者丁宁)7月22日晚间,复星医药(600196)发布公告称,公司控股子公司重庆药友制药有限责任公司于近日收到国家药品监督管理局关于如下药品注册申请获受理的通知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407223136898817.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407223136898817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"2453756727","title":"复星医药(600196.SH):硝普钠注射液及氟比洛芬酯注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2453756727","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453756727?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:55","pubTimestamp":1721638559,"startTime":"0","endTime":"0","summary":"截至2024年6月,集团现阶段针对新药1、新药2的累计研发投入分别约为人民币191万元、人民币2,811万元。公告称,新药1、新药2在进行商业化生产前,尚需获得药品注册批准等。本次获药品注册申请受理不会对本集团现阶段业绩产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0187","BK0239","02196","600196","BK1191","BK0096","BK0012","BK0028","BK0175","BK1593","BK0196","BK1515","BK0188","BK0060"],"gpt_icon":0},{"id":"2453507207","title":"复星医药(600196.SH,02196)深化CNS领域布局,合作产品全球首款128通道无液氦脑磁图仪获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2453507207","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453507207?lang=zh_cn&edition=full","pubTime":"2024-07-22 09:03","pubTimestamp":1721610193,"startTime":"0","endTime":"0","summary":"随着全球首款128通道无液氦脑磁图仪的成功上市,复星医疗器械将携手未磁科技,共同推动量子科技等脑科学领域前沿技术在脑疾病临床诊疗中的研究与应用,发展新质生产力,助力国产高科技装备高质量发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","600196","02196","BK0175","BK0183","BK1191","BK4135","BK1593","BK0096","BK0012","BK0196","CNS","BK0060","BK0028","BK0188","BK1515","BK0239"],"gpt_icon":0},{"id":"2453207837","title":"复星医药登榜“中国卓越管理公司”连续获奖企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2453207837","media":"复星医药","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453207837?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:47","pubTimestamp":1721609249,"startTime":"0","endTime":"0","summary":"2024年7月19日,第六届中国卓越管理公司颁奖盛典在广州举办,正式揭晓了备受业界期待的项目榜单。复星医药连续第二年登榜“中国卓越管理公司”,复星医药副董事长关晓晖作为获奖企业代表出席颁奖典礼。今年,复星医药还入选全球药企管线规模前二十强、荣登中央广播电视总台“中国ESG上市公司先锋100”榜及作为唯一药企案例入选新华社中国品牌全球传播故事榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072208503695e67ed6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072208503695e67ed6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0028","BK0175","600196","BK0188","BK0196","BK0187","BK0183","BK0012","BK0060","02196","BK0239"],"gpt_icon":0},{"id":"2453720474","title":"复星医药控股子公司复星医药产业与Kite Pharma拟对复星凯特进行同比例增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2453720474","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453720474?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:31","pubTimestamp":1721608294,"startTime":"0","endTime":"0","summary":"复星医药公布,2024年7月19日,公司控股子公司复星医药产业与 Kite Pharma、复星凯特签订《债权转股权及增资协议》,复星医药产业与Kite Pharma拟分别以各自对合营企业复星凯特享有的等值2850万美元存续债权转股对复星凯特进行同比例增资;其中:复星医药产业、Kite Pharma以对复星凯特分别享有的等值2850万美元存续债权本金均将转化为复星凯特新增注册资本2850万美元。本次增资款项主要用于复星凯特产品商业化和研发管线的投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhue2363203.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhue2363203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2453047412","title":"复星医药为控股子公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2453047412","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453047412?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:30","pubTimestamp":1721608241,"startTime":"0","endTime":"0","summary":"复星医药发布公告,该公司拟为控股子公司复星医药产业向渣打银行申请的融资项下债务提供最高额连带责任保证担保,该等债务本金不超过等值1.05亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhue2363039.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhue2363039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"2453204985","title":"复星医药控股股东质押8000万股及解除质押8000万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2453204985","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453204985?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:22","pubTimestamp":1721607738,"startTime":"0","endTime":"0","summary":"复星医药(02196)公布,公司于 2024 年 7 月 19 日接到控股股东上海复星高科技(集团)有限公司(以下简称“复星高科技”)的通知,其已就所持有的公司部分 A 股股份办理质押及解除质押手续。\n 2024 年 7 月 18 日,复星高科技质押8000万股公司股份予中国工商银行股份有限公司上海市长宁支行;同日,解除质押8000万股公司股份。\n 经复星高科技确认,本次解除质押的股份存在后续质押计划。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhuf9138295.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhuf9138295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2453820498","title":"复星医药控股子公司重庆凯林制药自主研发的硫代硫酸钠注射液获药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2453820498","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453820498?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:20","pubTimestamp":1721607649,"startTime":"0","endTime":"0","summary":"复星医药(02196)公布,公司控股子公司重庆凯林制药有限公司自主研发的硫代硫酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。\n 该新药为集团自主研发的化学药品,拟注册的适应症为用于氰化物中毒,也可用于砷、汞、铅、铋、碘等中毒。截至 2024 年 6 月,该集团现阶段针对该新药的累计研发投入约为人民币 107 万元(未经审计)。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhue2360588.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-22/doc-inceyhue2360588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1191","BK1593","01477","BK1515","02196","BK1574"],"gpt_icon":0},{"id":"2452653302","title":"招募复星系旧将,水井坊再迎新帅","url":"https://stock-news.laohu8.com/highlight/detail?id=2452653302","media":"国际金融报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452653302?lang=zh_cn&edition=full","pubTime":"2024-07-20 18:36","pubTimestamp":1721471793,"startTime":"0","endTime":"0","summary":"水井坊管理层再现变动。7月17日盘后,水井坊对外公告,经董事会提名委员会审查通过,公司董事会提名胡庭洲为公司第十一届董事会董事候选人。如果没有意外,胡庭洲将正式进入水井坊决策层。危永标离职后,朱镇豪开始担任水井坊代理总经理,并在2021年7月转正。今年一季度,水井坊营收同比增长9.38%至9.33亿元,归母净利润同比增长16.82%至1.86亿元,仍未回到2022年同期水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072018412495e20681&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072018412495e20681&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","00656","BK0215","02196","BK0021","600779"],"gpt_icon":0},{"id":"2452282038","title":"复星医药(600196)股东上海复星高科技(集团)有限公司质押8000万股,占总股本2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452282038","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452282038?lang=zh_cn&edition=full","pubTime":"2024-07-20 03:25","pubTimestamp":1721417122,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药7月20日公开信息显示,股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押8000.0万股,占总股本2.99%。质押详情见下表:截止本公告日,股东上海复星高科技(集团)有限公司已累计质押股份7.08亿股,占其持股总数的79.87%。复星医药主营业务:制药、医疗器械与医学诊断、医疗健康服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072000005299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","600196","02196","BK0175","BK0183","BK1191","BK1593","BK0096","BK0012","BK0196","BK0060","BK0028","BK0188","BK1515","BK0239"],"gpt_icon":0},{"id":"2452755394","title":"复星医药(02196)控股股东质押8000万股及解除质押8000万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2452755394","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452755394?lang=zh_cn&edition=full","pubTime":"2024-07-19 21:03","pubTimestamp":1721394216,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)公布,公司于 2024 年 7 月 19 日接到控股股东上海复星高科技(集团)有限公司(以下简称“复星高科技”)的通知,其已就所持有的公司部分 A 股股份办理质押及解除质押手续。2024 年 7 月 18 日,复星高科技质押8000万股公司股份予中国工商银行股份有限公司上海市长宁支行;同日,解除质押8000万股公司股份。经复星高科技确认,本次解除质押的股份存在后续质押计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0060","BK0096","BK0183","BK1191","600196","BK1515","BK0239","BK0028","BK0187","BK0012","02196","BK1593","BK0196","BK0175"],"gpt_icon":0},{"id":"2452473194","title":"复星医药(02196)控股子公司重庆凯林制药自主研发的硫代硫酸钠注射液获药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452473194","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452473194?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:57","pubTimestamp":1721393879,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)公布,公司控股子公司重庆凯林制药有限公司自主研发的硫代硫酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。该新药为集团自主研发的化学药品,拟注册的适应症为用于氰化物中毒,也可用于砷、汞、铅、铋、碘等中毒。截至 2024 年 6 月,该集团现阶段针对该新药的累计研发投入约为人民币 107 万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192059569f6bca1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192059569f6bca1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1515","02196","BK1191","BK1593","BK1574"],"gpt_icon":0},{"id":"2452475536","title":"复星医药(02196)为控股子公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2452475536","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452475536?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:57","pubTimestamp":1721393854,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,该公司拟为控股子公司复星医药产业向渣打银行申请的融资项下债务提供最高额连带责任保证担保,该等债务本金不超过等值1.05亿美元。该公司拟将向平安银行申请的等值人民币4亿元综合授信额度转授予控股子公司复星健康使用,并为复星健康于转授信额度项下债务提供连带责任保证担保;控股子公司复宏汉霖拟为其控股子公司汉霖医药向兴业银行申请的授信项下债务提供最高额连带责任保证担保,该等债务本金不超过人民币1000万元;控股子公司健嘉医疗拟为其控股子公司南昌健源康复向交通银行申请的融资项下债务提供最高额连带责任保证担保,该等债务不超过人民币2200万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0060","BK0196","02196","BK1515","BK0028","BK0188","BK1191","BK0239","BK0096","BK0175","BK0187","BK1593","600196","BK0012"],"gpt_icon":0},{"id":"2452354475","title":"复星医药最新公告:控股子公司药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452354475","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452354475?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:10","pubTimestamp":1721391058,"startTime":"0","endTime":"0","summary":"复星医药公告,控股子公司重庆凯林制药有限公司自主研发的硫代硫酸钠注射液药品注册申请近日获国家药品监督管理局受理。该新药用于氰化物中毒及砷、汞、铅、铋、碘等中毒。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900047886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK1593","02196","BK0187","600196","BK1515","BK0183","BK0196","BK0096","BK0060","BK0012","BK1191","BK0188","BK0175"],"gpt_icon":0},{"id":"2452542226","title":"复星医药(600196.SH)拟对合营企业复星凯特增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2452542226","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452542226?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:50","pubTimestamp":1721389844,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布公告,2024年7月19日,公司控股子公司复星医药产业与Kite Pharma、复星凯特签订《债权转股权及增资协议》,复星医药产业与Kite Pharma拟分别以各自对合营企业复星凯特享有的等值2850万美元存续债权转股对复星凯特进行同比例增资;其中:复星医药产业、Kite Pharma以对复星凯特分别享有的等值2850万美元存续债权本金均将转化为复星凯特新增注册资本2850万美元。据悉,复星凯特系集团之合营企业,主要从事肿瘤免疫细胞治疗产品的研发、生产和商业化。本次增资款项将主要用于复星凯特产品商业化和研发管线的投入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK1515","02196","BK0028","BK0175","BK1191","BK0188","BK1593","BK0196","BK0183","BK0187","BK0012","BK0239","BK0096","BK0060"],"gpt_icon":0},{"id":"2452422962","title":"复星医药(600196.SH):硫代硫酸钠注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452422962","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452422962?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:46","pubTimestamp":1721389587,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布公告,公司控股子公司重庆凯林制药有限公司自主研发的硫代硫酸钠注射液的药品注册申请于近日获国家药品监督管理局受理。该新药为集团自主研发的化学药品,拟注册的适应症为用于氰化物中毒,也可用于砷、汞、铅、铋、碘等中毒。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0096","BK0196","BK0012","BK0187","BK0060","BK1593","02196","BK0175","BK0239","BK1191","BK1515","BK0028","BK0188","600196"],"gpt_icon":0},{"id":"2452142642","title":"复星医药以国际标准推进质量管理 制药产线获WHO等权威组织国际认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2452142642","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452142642?lang=zh_cn&edition=full","pubTime":"2024-07-18 10:47","pubTimestamp":1721270832,"startTime":"0","endTime":"0","summary":"2024年07月15日,根据世界卫生组织官网消息,复星医药旗下桂林南药生产的莫纳皮拉韦胶囊200mg通过WHO药品预认证。今年2月,桂林南药口服制剂生产制造中心、注射剂生产制造中心、原料药生产制造中心等6条生产线再次通过世界卫生组织GMP检查,均符合国际GMP标准。2023年,复星医药旗下生产线接受国内外各类官方检查 100 余次、接受官方抽样超过600批次,均顺利通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2024071800019429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1191","BK1593","BK0239","600196","BK0060","BK0183","BK1515","BK0175","BK0187","02196","BK0196","01477","BK0096","BK0028","BK0188","BK1574"],"gpt_icon":0},{"id":"2452146024","title":"单抗概念盘中跳水,复星医药跌0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452146024","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452146024?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:52","pubTimestamp":1721267551,"startTime":"0","endTime":"0","summary":"07月18日,单抗概念盘中跳水,截至09点52分,单抗概念整体指数下跌0.57%,报1650.900点。从个股上来看,该概念的成分股中,复星医药跌0.09%,华东医药、天士力跌幅居前。从资金上来看,截止发稿,单抗概念概念主力净流入为-3476.45万,其中百奥泰受到资金热捧,主力净流入322.89万;拉长时间线来看,该板块近20日主力资金净流入-13.42亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718095231941f81eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718095231941f81eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","BK0188","BK0060","BK0183","BK0196","BK0012","BK0028","BK0239","BK0096","02196","BK0187","BK0175"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.0361},{"period":"3month","weight":0.1718},{"period":"6month","weight":-0.0536},{"period":"1year","weight":-0.316},{"period":"ytd","weight":-0.1894}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.049465},{"month":2,"riseRate":0.75,"avgChangeRate":0.030196},{"month":3,"riseRate":0.666667,"avgChangeRate":0.05388},{"month":4,"riseRate":0.416667,"avgChangeRate":0.038788},{"month":5,"riseRate":0.416667,"avgChangeRate":0.023536},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.030979},{"month":7,"riseRate":0.583333,"avgChangeRate":0.019921},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.057829},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.025941},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035528},{"month":11,"riseRate":0.5,"avgChangeRate":0.052861},{"month":12,"riseRate":0.5,"avgChangeRate":0.024492}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}